Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
Authors: Heidi L. Moline, Ariana P. Toepfer, Ayzsa Tannis, Geoffrey A. Weinberg, Mary A. Staat, Natasha B. Halasa, Julie A. Boom, Eileen J. Klein, John V. Williams, Jennifer E. Schuster, Leah Goldstein, Erin R. McKeever, Casey Kalman, Clinton Paden, Lydia Atherton, Megha Aggarwal, Pavitra Roychoudhury, Pedro A. Piedra, Leila C. Sahni, Laura S. Stewart, Rangaraj Selvarangan, Marian G. Michaels, Elizabeth P. Schlaudecker, Peter G. Szilagyi, Janet A. Englund, Benjamin R. Clopper, Natalie J. Thornburg, Gordana Derado, Meredith L. McMorrow, Fatimah S. Dawood, Christina Albertin, Justin Amarin, Heidi Arth, Vasanthi Avadhanula, Dithi Banerjee, Carla A Bartlett, Kristina Betters, Juan Castro, Eva Caudill, Jim Chappell, Peter Cook, Ximenia A Correa, Harshavardhan Doddapaneni, Dinah Dosdos, Wende Fregoe, Emma C Gauthier, Alexander Greninger, Hanna Grioni, Claudia Guevara, Olla Hamdan, Haya Hayek, Miranda Howard, Caymden Hughes, Sara Joan J Cregeen, Monika Johnson, Teresa Lin, Laura Loftis, Alyssa Masten, Nida Mohammad, Mary Moffat, Flor Munoz, Samar Musa, Donna M Muzny, Amy Ostrow, Amanda Payne, Christina Quigley, Collin Ragsdale, Marylin Rice, Chelsea Rohlfs, Anjana Sasidharan, Andrew Spieker, Bonnie Strelitz, Anil Surath, Tess Stopczynski, Ever Vega, Lijuan Wang, Gina Weddle, Krirsten Weltmer, Tricia Williams, Danielle Zerr
Journal: JAMA Pediatrics (2024)

Importance During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer’s maternal RSV vaccine. Postlicensure studies are needed to assess prevention product impact and effectiveness. Objective To compare the epidemiology and disease burden of medically attended RSV-associated acute respiratory illness (ARI) among children younger than 5 years during the 2023-2024 RSV season with 3 prepandemic RSV seasons (2017-2020), estimate nirsevimab effectiveness against medically attended RSV-associated ARI, and compare nirsevimab binding site mutations among circulating RSV in infants with and without nirsevimab receipt. Design, Setting, and Participants This study included a prospective population-based surveillance for medically attended ARI with systematic molecular testing for RSV and whole-genome sequencing of RSV positive samples, as well as a test-negative case-control design to estimate nirsevimab effectiveness. The study was conducted in 7 academic pediatric medical centers in the United States with data from RSV seasons (September 1 through April 30) in 2017 through 2024. Participants were children younger than 5 years with medically attended ARI. Exposure For the nirsevimab effectiveness analyses, nirsevimab receipt among infants younger than 8 months as of or born after October 1, 2023. Main Outcome and Measure Medically attended RSV-associated ARI. Results Overall, 28 689 children younger than 5 years with medically attended ARI were enrolled, including 9536 during September 1, 2023, through April 30, 2024, and 19 153 during the same calendar period of 2017-2020. Of these children, 16 196 (57%) were male, and 12 444 (43.4) were female; the median (IQR) age was 15 (6-29) months. During 2023-2024, the proportion of children with RSV was 23% (2199/9490) among all medically attended episodes, similar to 2017-2020. RSV-associated hospitalization rates in 2023-2024 were similar to average 2017-2020 seasonal rates with 5.0 (95% CI, 4.6-5.3) per 1000 among children younger than 5 years; the highest rates were among children aged 0 to 2 months (26.6; 95% CI, 23.0-30.2). Low maternal RSV vaccine uptake precluded assessment of effectiveness. Overall, 10 of 765 case patients (1%) who were RSV positive and 126 of 851 control patients (15%) who were RSV negative received nirsevimab. Nirsevimab effectiveness was 89% (95% CI, 79%-94%) against medically attended RSV-associated ARI and 93% (95% CI, 82%-97%) against RSV-associated hospitalization. Among 229 sequenced specimens, there were no differences in nirsevimab binding site mutations by infant nirsevimab receipt status. Conclusions and Relevance This analysis documented the continued high burden of medically attended RSV-associated ARI among young children in the US. There is a potential for substantial public health impact with increased and equitable prevention product coverage in future seasons.